Trimethoprim-sulfamethoxazole treatment for meningitis owing to multidrug-resistant Elizabethkingia meningoseptica in an extremely low-birthweight, premature infant

Paediatr Int Child Health. 2012 Aug;32(3):177-9. doi: 10.1179/2046905511Y.0000000008.

Abstract

Elizabethkingia meningoseptica is a recognised cause of meningitis in premature neonates and severe infections in immunocompromised adults; multi-drug resistance is a major issue. A premature infant developed sepsis, meningitis and hydrocephalus owing to E. meningoseptica and was treated successfully with trimethoprim-sulfamethoxazole (TMP-SMZ) for 3 weeks. A ventriculoperitoneal shunt was required for hydrocephalus. This is the youngest patient with meningitis caused by E. meningoseptica to have responded to TMP-SMZ.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents / administration & dosage*
  • Brain / diagnostic imaging
  • Drug Resistance, Multiple, Bacterial*
  • Female
  • Flavobacteriaceae / drug effects
  • Flavobacteriaceae / isolation & purification*
  • Flavobacteriaceae Infections / diagnosis*
  • Flavobacteriaceae Infections / drug therapy
  • Flavobacteriaceae Infections / microbiology
  • Humans
  • Hydrocephalus / diagnosis
  • Hydrocephalus / etiology
  • Hydrocephalus / surgery
  • Infant, Low Birth Weight
  • Infant, Newborn
  • Infant, Premature
  • Meningitis / complications
  • Meningitis / diagnosis*
  • Meningitis / drug therapy
  • Meningitis / microbiology
  • Sepsis / complications
  • Sepsis / diagnosis
  • Sepsis / drug therapy
  • Sepsis / microbiology
  • Tomography, X-Ray Computed
  • Trimethoprim, Sulfamethoxazole Drug Combination / administration & dosage*
  • Ventriculoperitoneal Shunt

Substances

  • Anti-Bacterial Agents
  • Trimethoprim, Sulfamethoxazole Drug Combination